CRISPR 'genetic screens' and new approaches to drug design have provided a potential new therapy, which blocks the progression of synovial sarcoma tumors in pre-clinical trials.
Rutgers scientists have developed catalysts that can convert carbon dioxide -- the main cause of global warming -- into plastics, fabrics, resins and other products.
One of the body's largest macromolecules is the machinery that gloms onto DNA and transcribes it into mRNA, the blueprint for proteins. But the molecule, TFIID, is complex with lots of floppy appendages, which makes it hard to obtain a clear picture of its structure. Using state-of-the-art cryo-electron microscopy detectors and computer analysis, UC Berkeley scientists have captured unprecedented detail of how TFIID's structure changes as it binds to DNA and recruits other proteins.
Controlled ingestion of peanut protein could help build tolerance in peanut allergy sufferers. Authors of a new study published in the New England Journal of Medicine say an oral immunotherapy drug they tested could be the first FDA-approved medication of its kind for people with peanut allergy. The medication, called AR101, is derived from peanut protein.
Scientists from the University of Bristol have designed a new synthetic glucose binding molecule platform that brings us one step closer to the development of the world's first glucose-responsive insulin which, say researchers, will transform the treatment of diabetes.
One in five people with Alzheimer's disease (AD) who use a benzodiazepine are also concomitant users of an opioid, according to a new study from the University of Eastern Finland. Concomitant use was more common in comparison persons, but those with AD used strong opioids more frequently. About half of all concomitant users were prolonged users whose use of these drugs had continued for more than three consecutive months.
Myotubular myopathy is a severe genetic disease that leads to muscle paralysis. Although no treatment currently exists, researchers from the UNIGE-with the University of Strasbourg,- have identified a molecule that not only greatly reduces the progression of the disease but also boosts life expectancy in animal models by a factor of seven. Since the molecule -- known as tamoxifen -- is already used for breast cancer, the researchers hope to soon set up a clinical trial.
Lowering mutation rates in harmful bacteria might be an as yet untried way to hinder the emergence of antimicrobial pathogens. One target for drug development might be a protein factor, DNA translocase Mfd, that enables bacteria to evolve rapidly by promoting mutations in many different bacterial species. This action speeds antibiotic resistance, including multi-drug resistance. Working on drugs to block Mfd and similar factors could be a revolutionary strategy to address the worldwide crisis of treatment-resistant infectious diseases.
Researchers from Würzburg and Toyama have discovered that a compound isolated from tropical rainforest vines inhibits the growth of pancreatic cancer cells in the lab.
For children and adults with food allergies, personal self-injectable epinephrine devices are crucial to treating severe reactions such as anaphylaxis if there is unintended exposure to allergens. Autoinjectors have become very expensive, although the drug they inject is cheap. In this study of simulated children with peanut allergy, researchers estimated value-based pricing for the devices, which is a method of drug pricing where drug costs are based on the magnitude of the benefit they provide.